267 related articles for article (PubMed ID: 11105184)
41. [Fabry disease in childhood].
Chabrol B; Mansour H; Cano A
Presse Med; 2007 Mar; 36 Spec No 1():1S32-5. PubMed ID: 17546765
[TBL] [Abstract][Full Text] [Related]
42. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
43. Anderson-Fabry disease: developments in diagnosis and treatment.
Kes VB; Cesarik M; Zavoreo I; Madzar Z; Demarin V
Acta Clin Croat; 2012 Sep; 51(3):411-7. PubMed ID: 23330407
[TBL] [Abstract][Full Text] [Related]
44. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
45. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
[TBL] [Abstract][Full Text] [Related]
46. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
47. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
48. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
49. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
50. Enzyme replacement therapy of Fabry disease.
Clarke JT; Iwanochko RM
Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
[TBL] [Abstract][Full Text] [Related]
51. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
52. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
53. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
Germain DP
J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
[TBL] [Abstract][Full Text] [Related]
54. [Fabry's disease; towards a treatment].
Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
[TBL] [Abstract][Full Text] [Related]
55. Natural history of the cerebrovascular complications of Fabry disease.
Mehta A; Ginsberg L;
Acta Paediatr Suppl; 2005 Mar; 94(447):24-7; discussion 9-10. PubMed ID: 15895708
[TBL] [Abstract][Full Text] [Related]
56. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
57. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
58. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.
Ziegler RJ; Lonning SM; Armentano D; Li C; Souza DW; Cherry M; Ford C; Barbon CM; Desnick RJ; Gao G; Wilson JM; Peluso R; Godwin S; Carter BJ; Gregory RJ; Wadsworth SC; Cheng SH
Mol Ther; 2004 Feb; 9(2):231-40. PubMed ID: 14759807
[TBL] [Abstract][Full Text] [Related]
59. [Fabry disease in light of recent review].
Uyama E
Brain Nerve; 2008 Nov; 60(11):1235-44. PubMed ID: 19069157
[TBL] [Abstract][Full Text] [Related]
60. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]